DESAIN VAKSIN MULTI-EPITOP COVID-19 DARI PROTEIN S DAN NSP3 VIRUS SARS-COV2 MELALUI PENDEKATAN REVERSE VACCINOLOGY

• Main Author: Leo Fany Siregar, Agust
• Format: Final Project
• Language: Indonesia
• Online Access: https://digilib.itb.ac.id/gdl/view/55604
• Institution: Institut Teknologi Bandung

The COVID-19 pandemic caused by the SARS-CoV2 virus has disrupted the economic and social stability of communities worldwide. So far, there have been 149 million positive cases and 3.1 million deaths due to the SARS CoV-2 virus infection. One of the most effective treatment to overcome this pandemic is vaccination. Spike protein responsible for the process of viral infection against host cells and Non-structural protein (NSP3) plays a role in viral polyproteins processing. Both of them was predicted to have high antigenicity and highly potential antigen for COVID-19 vaccine development. This study aims to determine COVID- 19 multi-epitope vaccine design from S and NSP3 proteins of SARS-CoV2 through a reverse vaccinology approach. The CTL, HTL, and LBL epitopes are predicted using the NetCTL1.2, NetHCIIPan4.0 and BepiPred2.0 respectively. All selected epitopes and adjuvants were combined using a linker to form a multi-epitope vaccine construct. The 3D structural model of vaccine constructs was predicted using trRosetta and molecular docking analysis was performed with TLR and MHC using ClusPro2.0 and GalaxyPepDock. Codon optimization and in-silico cloning of the vaccine construct into the pET23(+) expression vector was carried out using Jcat and SnapGene. Thus, we obtain a multi-epitope vaccine design consisting of 4 CTL epitopes, 4 HTL epitopes, 3 LBL epitopes and cholera toxin B as an adjuvant whilst for. Ramachandran, Z-score and ERRAT score analysis is 90.6%, -6.00 and 73.52 respectively. Furthermore, molecular docking analysis shows that interaction between vaccine with TLR1/2, CTL epitopes-MHC I and HTL epitopes-MHC II occur spontaneously or energetically feasible. Finally, codon optimization and in-silico cloning show that the vaccine design can be expressed effectively using the E. coli BL21(DE3) expression system with a CAI score of 0.96. Overall, predicted the multi-epitope vaccine design from S and NSP3 proteins be able to induce both humoral and cellular immune responses, so that it has the potential to be used as a vaccine candidate to overcome the COVID-19 pandemic.